par Polastro, Laura;Aftimos, Philippe ;Awada, Ahmad
Référence Expert review of anticancer therapy, 14, 6, page (649-665)
Publication Publié, 2014
Article révisé par les pairs
Résumé : In the new era of 'precision' cancer medicine, new drug development has shifted from cytotoxic chemotherapy to molecularly targeted agents. Eribulin mesylate, a microtubule-destabilizing agent, is the only 'classical' cytotoxic agent approved for the treatment of breast cancer in the last 7 years. This synthetic analogue of halichondrin B, isolated from the marine sponge 'Halicondria Okaida', was responsible for prolonging overall survival of heavily pretreated metastatic breast cancer patients in a large Phase III trial. Eribulin is now under clinical development in earlier settings such as the neo-adjuvant and adjuvant settings. Furthermore, its unique mechanism of action and the absence of cross-resistance with taxanes have led to the design of clinical trials in multiple indications: bladder cancer, lung cancer, prostate cancer. The main adverse events are neutropenia, fatigue and peripheral neuropathy. ©2014 Informa UK, Ltd.